Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Gerd Walz(University of Freiburg), Kai‐Uwe Eckardt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Jens Nürnberger(University of Duisburg-Essen), Jens Gaedeke(Charité - Universitätsmedizin Berlin), Christoph Wanner(Universitätsklinikum Würzburg), Marwan Mannaa(Centre Virchow-Villermé), Wolfgang Arns(Lungenklinik Köln-Merheim), Bernhard Banas(University Medical Center), Hermann Pavenstädt(University Hospital Münster), Harald Gschaidmeier(Novartis (Germany)), Klemens Budde(Charité - Universitätsmedizin Berlin), Ulrich Kunzendorf(University Hospital Schleswig-Holstein), Claudia Sommerer(Heidelberg University), Martin Büchert(University Medical Center Freiburg), Christoph May(Novartis (Germany)), Nicholas Obermüller(Goethe University Frankfurt), Walter H. Hörl(Medical University of Vienna), Stefan Krämer(Novartis (Germany))
Cited by 574
Related Papers
Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
|Kidney International|2005|3.9k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
|Kidney International|2010|2.3k
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
|New England Journal of Medicine|2006|2.1k